Can a Low-Dose steroid tame Immunotherapy's liver side effect?

NCT ID NCT07167251

Recruiting now Disease control Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times

Summary

This study looks at whether a low dose of the steroid prednisolone can control liver inflammation (hepatitis) that sometimes happens as a side effect of cancer immunotherapy. About 63 cancer patients who develop moderate to severe liver inflammation will receive a low steroid dose. The goal is to see if this approach resolves the liver problem without needing higher doses or extra medications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Royal Marsden Hospital
NOT_YET_RECRUITING

London, SW3 6JJ, United Kingdom
University Hospital Basel
RECRUITING

Basel, Canton of Basel-City, 4031, Switzerland

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CANCER IMMUNE RELATED ADVERSE EVENTS IMMUNE-MEDIATED HEPATITIS